-
Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours
-
Zelluna Completes First GMP Batch of ZI-MA4-1, a Novel TCR-NK Cell Therapy, to Treat Patients in Upcoming First-in-Human Trial
-
Zelluna ASA: Cancellation of subsequent repair offering
-
Zelluna ASA – Mandatory notification of trade
-
Zelluna ASA: New share capital registered
-
Zelluna ASA Announces Appointment of Geir Christian Melen as New Chief Financial Officer
-
Zelluna ASA: Disclosure of large shareholding
-
Zelluna ASA – Extraordinary General Meeting held on November 25, 2025
-
Zelluna ASA: New share capital registered
-
Zelluna ASA: Notice of extraordinary general meeting on 25 November 2025
